People living with hemophilia face a 46% higher risk of bone fractures than the general population, with that risk increasing for those with severe disease or a history of treatment-blocking antibodies. These are the findings of a large-scale Canadian study that highlights a growing health concern for patients as…
News
A new digital medical device, called florio HAEMO, may support more personalized care and help people with hemophilia better plan daily activities and live their normal life, a study suggests. The device helps patients and clinicians monitor real-world, real-time data on treatment and clinical outcomes, including pain, bleeding, well-being, and…
A structured rehabilitation program improved knee function, movement, and pain in people with hemophilia after total knee arthroplasty, a surgical procedure that replaces the knee joint, according to a 10-year study in China. While improvements were seen across patients with varying levels of knee mobility before surgery, those who…
Altuviiio (efanesoctocog alfa) reduced bleeding and was safe for boys and young men with severe hemophilia A, according to a recent study. Researchers also reported an increase in participants’ confidence in everyday activities and no return of neutralizing antibodies that may inhibit treatment, even in patients who are usually…
Note: This story was updated Jan. 20, 2026, to correct data on the number of boys on preventive FIX replacement therapy at the time of the analysis. Using longer-acting factor IX (FIX) products — known as extended half-life (EHL) products, or EHL-FIX — safely reduced factor use and helped children…
People with hemophilia A and their caregivers, as well as healthcare providers, have shown a strong interest in a new blood-testing device being developed to make blood clotting tests faster and easier to access, according to a recent study. The device, called EnzySystem, allows for measuring the activity of…
A new study highlights a hidden emotional burden for families living with hemophilia: the deep sense of guilt felt by parents, particularly mothers, who pass the condition on to their children. However, researchers found that this weight can be significantly lifted through better access to medical information, professional counseling,…
After five years of follow-up, Hemgenix (etranacogene dezaparvovec-drlb) was associated with durable factor IX (FIX) levels, lower bleeding rates, and a substantial reduction in the need for regular FIX infusions, with a generally favorable long-term safety profile in men with severe or moderately severe hemophilia B. These data…
In 2025, Hemophilia News Today delivered readers timely reporting on research, therapeutic options, and clinical trials for hemophilia. Below is a list of the top five most-read stories we published this year. As we enter 2026, we look forward to continuing to support and serve as a source…
BBM-H901 (dalnacogene ponparvovec), a gene therapy that’s approved in China for adults with moderate to severe hemophilia B, was shown to significantly reduce bleeding rates among hemophilia B patients in clinical trials, a new study shows. Hemophilia B is a genetic disorder caused by mutations in the gene that…
Recent Posts
- January’s reset means the system restarts, but our bodies do not
- People with hemophilia face 46% higher risk of bone fractures
- It’s important to find moments of joy amid the darkness of hemophilia
- With hemophilia, time went from standing still to flying by
- An unsettling dream reinforced the importance of building connections